Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas

Mass General Brigham

Status

Completed

Conditions

Bone Sarcoma

Non-rhabdomyosarcoma Soft Tissue Sarcoma

Treatments

Radiation: Proton Beam Radiation

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00592293

05-326

Other (Other Grant/Funding Number)

Details and patient eligibility

About

The main purpose of this study is to assess the short term and the long term side effects of proton beam radiation for pediatric bone and non-rhabdomyosarcoma soft tissue sarcomas.

Full description

Participants will receive radiation treatments once per day, 5 days a week for a total of 4 to 6 weeks, depending on how much total dose the tumor requires. The radiation doctor will see the participant once each week to monitor and record any side effects they may have from radiation treatment.
A special device will be made for each participant to help them hold still during the treatment. This may either be a mask or foam cradle, depending on the area to be treated.

Enrollment

70 patients

Sex

All

Ages

Under 30 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Biopsy proven Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) or bone sarcoma
Less than or equal to 30 years of age
Patients must have been treated with a standardly accepted chemotherapy regimen if chemotherapy is indicated
Patients must be willing to receive follow-up care for a minimum of five years after treatment at MGH and annual visits unless it is too difficult to return to MGH for follow-up care. In that event, the patient or guardian must be willing to have their outside medical information released in order to track the results of treatment
They or their legal guardian must give their informed consent
Timing of radiation may be according to concurrent protocol

Exclusion criteria

Co-morbidities that would make the use of radiation too toxic to deliver safely, such as serious local injury of collagen vascular disease
Patients who are pregnant
Previous treatment with radiation therapy
Concurrent adriamycin or gemcitabine chemotherapy is planned, unless on a concurrent protocol